Related Experiment Video
Updated: Jul 12, 2026

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
Glutamate uptake is reduced in prefrontal cortex in Huntington's disease
Bjørnar Hassel1, Shoshi Tessler, Richard L M Faull
1Norwegian Defense Research Establishment, P.O. Box 25, 2027 Kjeller, Norway. bjornar.hassel@ffi.no
Insights
Huntington's disease (HD) involves CAG repeat expansion, leading to impaired glutamate uptake in the brain. This dysfunction may contribute to neuronal damage in HD patients.
Area of Science:
- Neuroscience
- Genetics
- Neurodegenerative Diseases
Background:
- Huntington's disease (HD) is a genetic disorder caused by CAG repeat expansion in the HD gene.
- The exact mechanisms by which this mutation leads to neuronal dysfunction and degeneration remain unclear.
- Previous studies in animals with long CAG repeats indicated potential inhibition of glutamate uptake.
Purpose of the Study:
- To investigate the role of glutamate uptake impairment in the pathophysiology of Huntington's disease.
- To correlate CAG repeat expansion size with disease severity and glutamate transporter function in HD patients.
Main Methods:
- Analysis of post-mortem brain tissue from seven HD patients with moderate CAG expansions (40-52 repeats).
- Measurement of [(3)H]glutamate uptake in the prefrontal cortex.
- Assessment of synaptic and astrocytic markers, including synaptophysin, AMPA receptors, GFAP, and glutamate transporter EAAT1.
- Evaluation of the effect of dithiothreitol on glutamate uptake in control and HD brains.
Main Results:
- A strong correlation was found between CAG repeat expansion size and HD grade at autopsy (r=0.88, p=0.0002).
- Glutamate uptake was significantly reduced by 43% in the prefrontal cortex of HD patients.
- Glutamate uptake showed an inverse correlation with CAG repeat expansion (r= -0.82, p=0.015).
- Synaptic and astrocytic marker levels remained unchanged in HD brains.
- Dithiothreitol improved glutamate uptake in control brains but not in HD brains, suggesting irreversible oxidation of glutamate transporters.
Conclusions:
- Impairment of glutamate uptake is a significant finding in Huntington's disease brains with moderate CAG expansions.
- Reduced glutamate uptake may be due to irreversible oxidation of glutamate transporters.
- This impairment in glutamate transport function likely contributes to neuronal dysfunction and degeneration observed in Huntington's disease.
Abstract:
Huntington's disease (HD) is caused by a CAG repeat expansion in the HD gene, but how this mutation causes neuronal dysfunction and degeneration is unclear. Inhibition of glutamate uptake, which could cause excessive stimulation of glutamate receptors, has been found in animals carrying very long CAG repeats in the HD gene. In seven HD patients with moderate CAG expansions (40-52), repeat expansion and HD grade at autopsy were strongly correlated (r=0.88, p=0.0002). Uptake of [(3)H]glutamate was reduced by 43% in prefrontal cortex, but the level of synaptic (synaptophysin, AMPA receptors) and astrocytic markers (GFAP, glutamate transporter EAAT1) were unchanged. Glutamate uptake correlated inversely with CAG repeat expansion (r= -0.82, p=0.015). The reducing agent dithiothreitol improved glutamate uptake in controls, but not in HD brains, suggesting irreversible oxidation of glutamate transporters in HD. We conclude that impairment of glutamate uptake may contribute to neuronal dysfunction and degeneration in HD.
Related Concept Videos
Huntington Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
